Key result
Empagliflozin linked to a ~30 PRU reduction in platelet reactivity in stable CAD and T2D.
Why the study?
This study aimed to assess the effect of the sodium-glucose cotransporter 2 inhibitor empagliflozin on platelet reactivity in patients with stable coronary artery disease.
Does empagliflozin reduce platelet reactivity in patients with stable coronary artery disease?
Does empagliflozin reduce platelet reactivity in patients with stable coronary artery disease?
Mean Difference: 29.9 (95% CI 3.17–56.63)
Absolute Event Rate: 187.35% vs 217.25%
p-value: p=<0.030
Empagliflozin significantly attenuates platelet reactivity in patients with stable coronary artery disease, suggesting a potential pleiotropic antithrombotic effect.
No takes yet. Share an insight, caveat, or question.
May indicate antiplatelet effects of empagliflozin; leaves open relevance to clinical outcomes.
Seecheran et al. (2020) studied Stable coronary artery disease and type 2 diabetes mellitus (n=20). Empagliflozin vs. Baseline (without empagliflozin) was evaluated on Platelet reactivity (P2Y12 reaction units) (MD 29.90, 95% CI 3.17-56.63, p=<0.030). Empagliflozin significantly reduced platelet reactivity by a mean difference of 29.90 P2Y12 reaction units compared to baseline in patients with stable coronary artery disease and type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: